Wolfgang Jilg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wolfgang Jilg has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Juergen J. Wenzel
National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Medical Center Regensburg, Regensburg, Germany
4 shared publications Hans Wolf
Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
2 shared publications- Adrian Caplanusi
12GlaxoSmithKline Vaccines, Wavre, Belgium
1 shared publication - Angkool Kerdpanich
Infectious Diseases Unit, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand
1 shared publication - Anita Zitzmann
Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany
1 shared publication - Annika Gauss
Department of Gastroenterology and Hepatology, Heidelberg University Hospital, Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 16 September 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 435
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).
- 16 September 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 435
Open AccessExtended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).
- Open Access
- 2 October 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 334
Chronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report
Acute hepatitis E virus infection may cause mild, self-limiting hepatitis, either as epidemic outbreaks or sporadic cases, the latter of which have been reported in industrialized countries. Chronic infections are uncommon and have been reported in immunosuppressed patients, patients with human immunodeficiency virus infection, and patients with hematological malignancies.
- 2 October 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 334
Open AccessChronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report
Acute hepatitis E virus infection may cause mild, self-limiting hepatitis, either as epidemic outbreaks or sporadic cases, the latter of which have been reported in industrialized countries. Chronic infections are uncommon and have been reported in immunosuppressed patients, patients with human immunodeficiency virus infection, and patients with hematological malignancies.
- 30 December 2010
- Published by Wiley in Pharmazie in unserer Zeit
- Vol. 40 (1) , 36-43
Impfstoffe gegen die Virushepatitiden A bis E. Was haben sie bewirkt, was können sie bewirken?
- 30 December 2010
- Published by Wiley in Pharmazie in unserer Zeit
- Vol. 40 (1) , 36-43
Impfstoffe gegen die Virushepatitiden A bis E. Was haben sie bewirkt, was können sie bewirken?
- Open Access
- 1 December 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (12) , 2218-2222
Library of Prefabricated Locked Nucleic Acid Hydrolysis Probes Facilitates Rapid Development of Reverse-Transcription Quantitative Real-Time PCR Assays for Detection of Novel Influenza A/H1N1/09 Virus
Background: The emergence of a novel pandemic human strain of influenza A (H1N1/09) has clearly demonstrated the need for flexible tools enabling the rapid development of new diagnostic methods. Methods: We designed a set of reverse-transcription quantitative real-time PCR (RT-qPCR) assays based on the Universal ProbeLibrary (UPL)—a collection of 165 presynthesized, fluorescence-labeled locked nucleic acid (LNA) hydrolysis probes—specifically to detect the novel influenza A virus. We evaluated candidate primer/UPL-probe pairs with 28 novel influenza A/H1N1/09 patient samples of European and Mexican origin. Results: Of 14 assays in the hemagglutinin (HA) and neuraminidase (NA) genes, 12 detected viral nucleic acids from diluted patient samples without need for further optimization. We characterized the diagnostic specificity of the 2 best-performing assays with a set of samples comprising various influenza virus strains of human and animal origin that showed no cross-reactivity. The diagnostic sensitivity of these 2 primer/probe combinations was in the range of 100–1000 genomic copies/mL. In comparison to a reference assay recommended by the German health authorities, the analytical sensitivities and specificities of the assays were equivalent. Conclusions: Facing the emergence of novel influenza A/H1N1/09, we were able to develop, within 2 days, a set of sensitive and specific RT-qPCR assays for the laboratory diagnosis of suspected cases. H1N1/09 served as a model to show the feasibility of the UPL approach for the expedited development of new diagnostic assays to detect emerging pathogens.
- 1 December 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (12) , 2218-2222
Open AccessLibrary of Prefabricated Locked Nucleic Acid Hydrolysis Probes Facilitates Rapid Development of Reverse-Transcription Quantitative Real-Time PCR Assays for Detection of Novel Influenza A/H1N1/09 Virus
Background: The emergence of a novel pandemic human strain of influenza A (H1N1/09) has clearly demonstrated the need for flexible tools enabling the rapid development of new diagnostic methods. Methods: We designed a set of reverse-transcription quantitative real-time PCR (RT-qPCR) assays based on the Universal ProbeLibrary (UPL)—a collection of 165 presynthesized, fluorescence-labeled locked nucleic acid (LNA) hydrolysis probes—specifically to detect the novel influenza A virus. We evaluated candidate primer/UPL-probe pairs with 28 novel influenza A/H1N1/09 patient samples of European and Mexican origin. Results: Of 14 assays in the hemagglutinin (HA) and neuraminidase (NA) genes, 12 detected viral nucleic acids from diluted patient samples without need for further optimization. We characterized the diagnostic specificity of the 2 best-performing assays with a set of samples comprising various influenza virus strains of human and animal origin that showed no cross-reactivity. The diagnostic sensitivity of these 2 primer/probe combinations was in the range of 100–1000 genomic copies/mL. In comparison to a reference assay recommended by the German health authorities, the analytical sensitivities and specificities of the assays were equivalent. Conclusions: Facing the emergence of novel influenza A/H1N1/09, we were able to develop, within 2 days, a set of sensitive and specific RT-qPCR assays for the laboratory diagnosis of suspected cases. H1N1/09 served as a model to show the feasibility of the UPL approach for the expedited development of new diagnostic assays to detect emerging pathogens.
- 16 August 2004
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 42 (08) , 698-702
Immunprophylaxe der Hepatitis B
Konsens Entsprechend den Empfehlungen der Ständigen Impfkommission am Robert Koch-Institut (STIKO) sollen alle Säuglinge ab vollendetem 2. Lebensmonat geimpft werden, alle noch nicht geimpften Kinder und Jugendlichen bis zum vollendeten 17. Lebensjahr, möglichst vor Eintritt der Pubertät, sowie die in der Indikationsliste der STIKO aufgeführten Personen mit erhöhtem Hepatitis-B-Risiko (B/C). Erläuterung Ziel der Impfempfehlungen [ 1 ] ist die Durchimpfung der gesamten Bevölkerung. Die nach der Einführung der Impfung in den Ländern mit geringer Hepatitis-B-Prävalenz zunächst geübte Strategie, nur Angehörige bestimmter Risikogruppen zu impfen, konnte die Hepatitis-B-Inzidenz in diesen Ländern nur geringfügig senken. Hauptgrund dafür dürfte die Tatsache sein, dass ein Großteil der Infektionen sexuell übertragen wird, in der Mehrzahl bei Menschen, die sich keiner der „typischen” Risikogruppen zugehörig fühlen [ 2 ]. Deshalb empfahl die Weltgesundheitsorganisation im Jahre 1992 allen Ländern die generelle Impfung gegen Hepatitis B. Durch die weltweite Durchsetzung dieser Empfehlung kann die Hepatitis B langfristig ausgerottet werden, da der Mensch der einzige epidemiologisch relevante Wirt des Erregers ist. Die Impfempfehlung ist in Deutschland auf die ersten 18 Lebensjahre beschränkt, weil die öffentlichen und privaten Krankenkassen sich nur zur Finanzierung der generellen Impfung bei Kindern und Jugendlichen bereit erklären konnten. Daher ist es gegenwärtig von besonderer Wichtigkeit, darüber hinaus wenigstens die Erwachsenen mit einem erhöhten Hepatitis-B-Risiko zu impfen, wie sie in der Indikationsliste der STIKO (s. u.) aufgeführt sind. Die Kosten für diese Impfungen werden von den Krankenkassen bzw. im Falle einer beruflichen Gefährdung vom Arbeitgeber getragen.
- 16 August 2004
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 42 (08) , 698-702
Immunprophylaxe der Hepatitis B
Konsens Entsprechend den Empfehlungen der Ständigen Impfkommission am Robert Koch-Institut (STIKO) sollen alle Säuglinge ab vollendetem 2. Lebensmonat geimpft werden, alle noch nicht geimpften Kinder und Jugendlichen bis zum vollendeten 17. Lebensjahr, möglichst vor Eintritt der Pubertät, sowie die in der Indikationsliste der STIKO aufgeführten Personen mit erhöhtem Hepatitis-B-Risiko (B/C). Erläuterung Ziel der Impfempfehlungen [ 1 ] ist die Durchimpfung der gesamten Bevölkerung. Die nach der Einführung der Impfung in den Ländern mit geringer Hepatitis-B-Prävalenz zunächst geübte Strategie, nur Angehörige bestimmter Risikogruppen zu impfen, konnte die Hepatitis-B-Inzidenz in diesen Ländern nur geringfügig senken. Hauptgrund dafür dürfte die Tatsache sein, dass ein Großteil der Infektionen sexuell übertragen wird, in der Mehrzahl bei Menschen, die sich keiner der „typischen” Risikogruppen zugehörig fühlen [ 2 ]. Deshalb empfahl die Weltgesundheitsorganisation im Jahre 1992 allen Ländern die generelle Impfung gegen Hepatitis B. Durch die weltweite Durchsetzung dieser Empfehlung kann die Hepatitis B langfristig ausgerottet werden, da der Mensch der einzige epidemiologisch relevante Wirt des Erregers ist. Die Impfempfehlung ist in Deutschland auf die ersten 18 Lebensjahre beschränkt, weil die öffentlichen und privaten Krankenkassen sich nur zur Finanzierung der generellen Impfung bei Kindern und Jugendlichen bereit erklären konnten. Daher ist es gegenwärtig von besonderer Wichtigkeit, darüber hinaus wenigstens die Erwachsenen mit einem erhöhten Hepatitis-B-Risiko zu impfen, wie sie in der Indikationsliste der STIKO (s. u.) aufgeführt sind. Die Kosten für diese Impfungen werden von den Krankenkassen bzw. im Falle einer beruflichen Gefährdung vom Arbeitgeber getragen.
- 1 June 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (6) , 777-778
Hepatitis-B-Impfstrategie bei Beschäftigten im Gesundheitswesen
- 1 June 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (6) , 777-778
Hepatitis-B-Impfstrategie bei Beschäftigten im Gesundheitswesen
- 15 November 2001
- Vol. 143 (46) , 30-5
[Adults tired of vaccines. Ask your patients about vaccine protection!].
In general, vaccinations can be divided into standard and indication-related vaccinations. The former, which are mandatory for adults too, include tetanus and diphtheria, and those against influenza and pneumococci in people older than 60. The term indication vaccinations is used to describe those that are recommended in certain situations, for example, in the presence of a particular occupational risk, in certain underlying diseases, or particular situations, e.g. women of childbearing age, people living in regions endemic for meningoencephalitis, and drug addicts. Since the vaccination rate in the case of adults leaves much to be desired, all physicians should be required to ensure that "gaps" are closed and immunization protection is maintained.
- 15 November 2001
- Vol. 143 (46) , 30-5
[Adults tired of vaccines. Ask your patients about vaccine protection!].
In general, vaccinations can be divided into standard and indication-related vaccinations. The former, which are mandatory for adults too, include tetanus and diphtheria, and those against influenza and pneumococci in people older than 60. The term indication vaccinations is used to describe those that are recommended in certain situations, for example, in the presence of a particular occupational risk, in certain underlying diseases, or particular situations, e.g. women of childbearing age, people living in regions endemic for meningoencephalitis, and drug addicts. Since the vaccination rate in the case of adults leaves much to be desired, all physicians should be required to ensure that "gaps" are closed and immunization protection is maintained.
- 1 April 2000
- Published by Springer Nature in Der Chirurg
- Vol. 71 (4) , 374-380
Epidemiologie, Diagnostik und Prophylaxe der Virushepatitiden
Viral hepatitis is one of the most important infectious diseases worldwide. It is frequent in tropical and subtropical areas, but also plays still a significant role in the industrialized countries of Northern and Western Europe and the USA. In Germany more than 100 000 people are infected by viral hepatitis each year. Whereas hepatitis A and E are transmitted fecal-orally, hepatitis B, C and D are transmitted by the parenteral route. Most hepatitis A infections seen in Germany are acquired abroad. Hepatitis B is still a nosocomial disease; the majority of infections in Germany, however, seems to be transmitted sexually. For the serological diagnosis of viral hepatitis a battery of sensitive tests for specific antibodies and antigens is available; usually testing of one serum sample allows an unambiguous diagnosis. Prophylaxis of hepatitis A and B is possible using safe and efficient vaccines.
- 1 April 2000
- Published by Springer Nature in Der Chirurg
- Vol. 71 (4) , 374-380
Epidemiologie, Diagnostik und Prophylaxe der Virushepatitiden
Viral hepatitis is one of the most important infectious diseases worldwide. It is frequent in tropical and subtropical areas, but also plays still a significant role in the industrialized countries of Northern and Western Europe and the USA. In Germany more than 100 000 people are infected by viral hepatitis each year. Whereas hepatitis A and E are transmitted fecal-orally, hepatitis B, C and D are transmitted by the parenteral route. Most hepatitis A infections seen in Germany are acquired abroad. Hepatitis B is still a nosocomial disease; the majority of infections in Germany, however, seems to be transmitted sexually. For the serological diagnosis of viral hepatitis a battery of sensitive tests for specific antibodies and antigens is available; usually testing of one serum sample allows an unambiguous diagnosis. Prophylaxis of hepatitis A and B is possible using safe and efficient vaccines.